Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
innovaTV 204: Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer
NCT03438396Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Jun 2018
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of tisotumab vedotin in Cervical Cancer (CC), sponsored by Seagen Inc.. Started Jun 2018; status: completed.
02
Drugs
tisotumab vedotin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03438396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03438396.